Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02775292
Title Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

Advanced Solid Tumor

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine

Nivolumab

NY-ESO-1 peptide vaccine

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.